Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2014

01-06-2014 | Research Article

Impact of generic substitution practice on care of diabetic patients

Authors: Olubukola O. Oyetunde, Bolajoko A. Aina, Fola Tayo

Published in: International Journal of Clinical Pharmacy | Issue 3/2014

Login to get access

Abstract

Background Patients with chronic diseases like type II diabetes mellitus often have their prescriptions substituted with generic medicines in the course of care to save costs of medicines and to improve access. There is need to assess impact of this practice on patient care. Objective To assess patient’s knowledge of generic substitution practice and its impact on patient care. Setting An outpatient diabetic clinic of a tertiary hospital in Nigeria. Method The study is a cross sectional survey of patients attending a diabetic clinic. A structured questionnaire was used to interview willing patients. A total of 120 patients were enrolled for the study, but only 102 responded (85 % overall response rate). Main outcome measures: Patients’ knowledge of generic substitution practice, patients’ report of abstaining from drug use, experiences of more side effects and patients’ confusion. Results Over half (57.8 %) of surveyed patients (n = 59) had noticed brand switches, out of which, 30.5 % experienced brand switches more than 3 times within a year. More than a third of the respondents (38.6 %) did not know when pharmacists actually substituted their medicines. About one in five (19.6 %) patients did not use their medicines after substitution because they were not sure of the brand supplied but 35.6 % have rejected substitution at one time and insisted on doctors’ prescription. Respondents (14.9 %) agreed that brand substitution resulted in confusion while 24 % reported receiving brands that resulted in more side effects. More respondents (58.6 %) indicated that they never had a discussion with their pharmacists about the reasons for generic substitution and switches. Conclusion Generic substitution without adequate information resulted in confusion and subsequent lack of adherence. There is the vital need for appropriate policy and guidelines for generic substitution in Nigeria.
Literature
1.
go back to reference Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1.PubMedCentralPubMedCrossRef Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1.PubMedCentralPubMedCrossRef
3.
go back to reference Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341–8.PubMedCrossRef Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341–8.PubMedCrossRef
5.
go back to reference Federman AD, Halm EA, Zhu C, Hochman T, Siu AL. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care. 2006;12(10):611–8.PubMedCentralPubMed Federman AD, Halm EA, Zhu C, Hochman T, Siu AL. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care. 2006;12(10):611–8.PubMedCentralPubMed
6.
go back to reference Fairman KA, Curtiss FR. The elephant in the pharmacy: patient choice is the big challenge that no one talks about in affordability of prescription drugs. (Editorial). J Manag Care Pharm. 2007;17(7):620–2. Fairman KA, Curtiss FR. The elephant in the pharmacy: patient choice is the big challenge that no one talks about in affordability of prescription drugs. (Editorial). J Manag Care Pharm. 2007;17(7):620–2.
7.
go back to reference Steinman MA, Chren MM, Landefeld CS. What’s in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med. 2007;22(5):645–8.PubMedCentralPubMedCrossRef Steinman MA, Chren MM, Landefeld CS. What’s in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med. 2007;22(5):645–8.PubMedCentralPubMedCrossRef
8.
go back to reference Reichert S, Simon T, Halm EA. Physicians’ attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med. 2000;160(18):2799–803.PubMedCrossRef Reichert S, Simon T, Halm EA. Physicians’ attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med. 2000;160(18):2799–803.PubMedCrossRef
9.
go back to reference Roberts RJ, Kauffman RE, Mirkin BL, Rumack BH, Snodgrass W, Spielberg SP. Generic prescribing, generic substitution and therapeutic substitution. Pediatrics. 1987;79:835. Roberts RJ, Kauffman RE, Mirkin BL, Rumack BH, Snodgrass W, Spielberg SP. Generic prescribing, generic substitution and therapeutic substitution. Pediatrics. 1987;79:835.
11.
go back to reference Holmes DR Jr, Becker JA, Granger CB, Limacher MC, Page RL 2nd, Sila C. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. [Internet] 2011 [cited 2013 Sept 29]; 124: 1290–1310. doi: 10.1161/CIR.0b013e31822d97d5. Holmes DR Jr, Becker JA, Granger CB, Limacher MC, Page RL 2nd, Sila C. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. [Internet] 2011 [cited 2013 Sept 29]; 124: 1290–1310. doi: 10.​1161/​CIR.​0b013e31822d97d5​.
12.
go back to reference The Medical Letter. Generic drugs. Med Lett Drugs Ther. 2002;44(1141):89–90. The Medical Letter. Generic drugs. Med Lett Drugs Ther. 2002;44(1141):89–90.
13.
go back to reference Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82(3):366–74.PubMedCrossRef Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82(3):366–74.PubMedCrossRef
14.
go back to reference Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 2000;51(3):149–62.PubMedCrossRef Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 2000;51(3):149–62.PubMedCrossRef
15.
go back to reference Hassali A, Stewart K, Kong D. Quality use of generic medicines. Austr Prescr. 2004;27(4):80–1. Hassali A, Stewart K, Kong D. Quality use of generic medicines. Austr Prescr. 2004;27(4):80–1.
17.
go back to reference Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A. Consumers’ views on generic medicines: a review of the literature. Int J Pharm Pract. 2009;17(2):79–88.PubMed Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A. Consumers’ views on generic medicines: a review of the literature. Int J Pharm Pract. 2009;17(2):79–88.PubMed
18.
go back to reference Kalisch LM, Roughead EE, Gilbert AL. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia. Pharmacoepidemiol Drug Saf. 2008;17(6):620–5.PubMedCrossRef Kalisch LM, Roughead EE, Gilbert AL. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia. Pharmacoepidemiol Drug Saf. 2008;17(6):620–5.PubMedCrossRef
19.
go back to reference Johnston A, Asmar R, Dahlöf B, Hill K, Jones DA, Jordan J, et al. Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. Br J Clin Pharmacol. 2011;72(5):727–30.PubMedCentralPubMedCrossRef Johnston A, Asmar R, Dahlöf B, Hill K, Jones DA, Jordan J, et al. Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. Br J Clin Pharmacol. 2011;72(5):727–30.PubMedCentralPubMedCrossRef
20.
go back to reference Vallès JA, Barreiro M, Cereza G, Ferro JJ, Martínez MJ, Escribà JM, et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy. 2003;65(3):269–75.PubMedCrossRef Vallès JA, Barreiro M, Cereza G, Ferro JJ, Martínez MJ, Escribà JM, et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy. 2003;65(3):269–75.PubMedCrossRef
21.
go back to reference Chong CP, March G, Clark A, Gilbert A, Hassali MA, Bahari MB. A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance. Health Policy. 2011;99(2):139–48.PubMedCrossRef Chong CP, March G, Clark A, Gilbert A, Hassali MA, Bahari MB. A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance. Health Policy. 2011;99(2):139–48.PubMedCrossRef
22.
go back to reference Hassali MA, Kong DC, Stewart K. Generic medicines: perceptions of consumers in Melbourne. Australia. Int J Pharm Pract. 2005;13(4):257–64.CrossRef Hassali MA, Kong DC, Stewart K. Generic medicines: perceptions of consumers in Melbourne. Australia. Int J Pharm Pract. 2005;13(4):257–64.CrossRef
23.
go back to reference Ganther JM, Kreling DH. Consumer perception of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc. 2000;40(3):378–83. Ganther JM, Kreling DH. Consumer perception of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc. 2000;40(3):378–83.
24.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.PubMedCrossRef Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.PubMedCrossRef
25.
go back to reference Enwere OO, Salako BL, Falade CO. Prescription and cost consideration at a diabetic clinic in Ibadan, Nigeria: a report. Ann Ib Postgrad Med. 2006;4:32–6. Enwere OO, Salako BL, Falade CO. Prescription and cost consideration at a diabetic clinic in Ibadan, Nigeria: a report. Ann Ib Postgrad Med. 2006;4:32–6.
26.
go back to reference Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumers’ views on generic medications. J Am Pharm Assoc. 2001;41(5):726–36. Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumers’ views on generic medications. J Am Pharm Assoc. 2001;41(5):726–36.
27.
go back to reference Simmenroth-Nayda A, Hummers-Pradier E, Ledig T, Jansen R, Niebling W, Bjerre L. et al. Prescription of generic drugs in general medical practice. Result of a survey of general medical practitioners. Med Klin (Munich) 2006; 9:705–10. PMID 16977394. Simmenroth-Nayda A, Hummers-Pradier E, Ledig T, Jansen R, Niebling W, Bjerre L. et al. Prescription of generic drugs in general medical practice. Result of a survey of general medical practitioners. Med Klin (Munich) 2006; 9:705–10. PMID 16977394.
28.
go back to reference Jimoh AO, Sabir AA, Chika A, Sani Z. Patterns of antidiabetic drug use in a diabetic outpatient clinic of a tertiary health institution Sokoto, north western Nigeria. J Med Sci. 2011;11(5):241–5.CrossRef Jimoh AO, Sabir AA, Chika A, Sani Z. Patterns of antidiabetic drug use in a diabetic outpatient clinic of a tertiary health institution Sokoto, north western Nigeria. J Med Sci. 2011;11(5):241–5.CrossRef
29.
go back to reference Uloko AE, Ofoegbu EN, Chinenye S, Fasanmade OA, Fasanmade AA, Ogbera AO, et al. Profile of Nigerians with diabetes mellitus: Diabcare Nigeria study group (2008): results of a multicenter study. Indian J Endocrinol Metab. 2012;116(4):558–64. Uloko AE, Ofoegbu EN, Chinenye S, Fasanmade OA, Fasanmade AA, Ogbera AO, et al. Profile of Nigerians with diabetes mellitus: Diabcare Nigeria study group (2008): results of a multicenter study. Indian J Endocrinol Metab. 2012;116(4):558–64.
30.
go back to reference Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy. 2012;104(1):61–8.PubMedCrossRef Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy. 2012;104(1):61–8.PubMedCrossRef
31.
go back to reference Ganther-Urmie JM, Nair KV, Valuck R, McCollum M, Lewis SJ, Turpin RS. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans. Am J Manag Care. 2004;10(3):201–8.PubMed Ganther-Urmie JM, Nair KV, Valuck R, McCollum M, Lewis SJ, Turpin RS. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans. Am J Manag Care. 2004;10(3):201–8.PubMed
32.
go back to reference Hassali MA, Kong DC, Stewart K. Generic drugs: perceptions of community pharmacists in Melbourne, Australia. J Pharm Financ Econ Policy. 2005;14(3):27–45.CrossRef Hassali MA, Kong DC, Stewart K. Generic drugs: perceptions of community pharmacists in Melbourne, Australia. J Pharm Financ Econ Policy. 2005;14(3):27–45.CrossRef
33.
go back to reference Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav. 2002;3(6):522–5.PubMedCrossRef Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav. 2002;3(6):522–5.PubMedCrossRef
34.
go back to reference Håkonsen H, Toverud EL. Special challenges for drug adherence following generic substitution in Pakistani immigrants living in Norway. Eur J Clin Pharmacol. 2011;67(2):193–201.PubMedCentralPubMedCrossRef Håkonsen H, Toverud EL. Special challenges for drug adherence following generic substitution in Pakistani immigrants living in Norway. Eur J Clin Pharmacol. 2011;67(2):193–201.PubMedCentralPubMedCrossRef
Metadata
Title
Impact of generic substitution practice on care of diabetic patients
Authors
Olubukola O. Oyetunde
Bolajoko A. Aina
Fola Tayo
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-9946-5

Other articles of this Issue 3/2014

International Journal of Clinical Pharmacy 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine